Mirna Therapeutics Report issue

For profit Phase 2
Founded: Austin TX United States (2007)
Status: Acquired by Synlogic (2017)

Organization Overview

First Clinical Trial
2013
NCT01829971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Mirna Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

mrx34 (2 trials)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2